Tuesday, 25 Feb 2020

You are here

Update on Checkpoint Inhibitor Safety

“Autoimmunity is the Achilles heel of onco-immunotherapy” per Dr. Leonard Calabrese, which leaves a dilemma for rheumatologists.

Onco-immunotherapy, or the use of checkpoint inhibitors (CTLA-4 agonists, or blockers of PD-1/PD-L1), is the blocking of T cell regulation of immune responses. Onco-immunotherapy induces immune dysregulation to allow patients to develop an immune response to their cancer cells. An unfortunate side effect for patients taking onco-immunotherapy is often autoimmune-like diseases referred to as immune adverse reactions (irAEs). Studies in France and the United States (Kostine Marie, presented in EULAR) have shown that irAEs can be a good prognostic sign, suggesting these therapies are working. Rheumatology is faced with new problems as onco-immunotherapies may induce new chronic diseases in multiple different forms secondary to the treatment. 

Between EULAR 2018 and ACR 2018 there has been increasing interest regarding irAEs. At this past ACR in November, multiple descriptive abstracts were presented discussing phenotypic risk stratification as well as treatment of irAE patients. Institutions have begun to develop multi-disciplinary tumor boards to discuss irAEs and dedicated irAEs clinics are being opened.

irAEs can affect any organ with a variety of autoimmune manifestations; these can include Sheehan’s Syndrome (infarct of the pituitary) and autoimmune induced hypothyroidism, as well as a myriad of all possible rheumatic disease related irAEs the most common are arthralgias, arthritis, myositis, PMR, intestinal nephritis and myocarditis. 20-43% of treated patients develop severe irAEs, with onset being drug dependent, but typically occurring within the first 12 weeks of immunotherapy exposure. 

There are over 10,000 patients who have already been treated with onco-immunotherapy drugs and more than 164 new onco-immunotherapies are in development. Questions arise over patients with pre-existing autoimmune diseases and whether the autoimmune disease become worse due to onco-immunotherapy treatments. Additionally, there are questions about patients with preexisting autoantibodies and whether or not they are at risk for developing symptomatic disease. As rheumatologist, a question emerges surrounding the treatment of patients with active cancer who now have upregulated immune systems. Traditionally, patients with certain cancers cannot be exposed to certain DMARDs or anti-TNFs. There are a growing number of case reports describing the use of such drugs to treat irAEs.

A consortium is being created to develop a multicenter longitudinal prospective registry, and an international effort to begin to identify potential risk markers as well as possible mitigating steps to decrease the incidence of these adverse effects. The consortium will additionally focus on creating a patient “voice in this” benefit-to-harm scenario. Patients are now faced with the “C” word and told they have cancer and might respond and can live; however, they may develop chronic autoimmune diseases related to the lifesaving therapy.  

In summary, irAEs will become more common with the use of onco-immunotherapy, thus as rheumatologist we will need to begin to develop a framework to risk stratify and understand treatment.

We know you have questions and the consortium is planning to work on developing guidelines and treatment options in a thoughtful collaborative manner. Please do not hesitate to email with questions at Alexa.meara@osumc.edu.


Rheumatologists' Comments

Very good review! Good synthesis about those dillemas can be read at a letter published in Annals of the Rheumatic Diseases: Checkpoint inhibitors and arthritis: Seeking balance between victories and defeats. Thanks!

More Like This

Overmedication of America

Recent research from the Lown Institute reports that 750 older Americans are hospitalized daily because of serious side effects from and the core problem is that of polypharmacy, especially in the elderly. 

Best of 2019 - Biologic Safety Guidelines from the British Society for Rheumatology

In the United Kingdom, NICE has looked to the British Society of Rheumatology (BSR) to develop evidence based guidance on the safe use of biologic DMARDs in patients with inflammatory arthritis. This guidance document on biologic safety covers baseline screening, monitoring, effect of co-morbidities, and when or under what circumstances biologic therapy should be interrupted.

Best of 2019 - Methotrexate and the Risk of Lung Disease

Rheumatology has a comprehensive overview of methotrexate (MTX) and the risk of lung injury, MTX-related pneumonitis and interstitial lung disease (RA-ILD) with rheumatoid arthritis (RA). Past reports suggest the frequence of MTX-pneumonitis to be between 0.3 and 11.6%; recent studies suggest it may be much lower.

No Cancer Risk with Systemic Necrotizing Vasculitis

The French Vasculitis Study Group has published that patients with systemic necrotizing vasculitis do not have an increased risk of malignancy; in fact they have a risk that is similar to the general population.

Previous reports have suggested either no risk or a declining risk in the era of better therapies for vasculitis. 

FDA Warns 15 CBD Manufacturers

Today, the U.S. Food and Drug Administration issued warning letters to 15 companies for illegally selling products containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act).  This warning affirms that the FDA has not determined the many preparations of cannabidiol to be safe or effective.